Skip to main content
. 2021 May 13;137(19):2634–2645. doi: 10.1182/blood.2020007512

Table 4.

ORRs in B-NHL subgroups treated with loncastuximab tesirine doses 15 to 200 µg (efficacy analysis set)

n (%)
DLBCL (n = 137) MCL (n = 15) FL (n = 14)
ORR 58 (42.3) 7 (46.7) 11 (78.6)
 95% CI 33.9-51.1 21.3-73.4 49.2-95.3
CR 32 (23.4) 5 (33.3) 9 (64.3)
PR 26 (19.0) 2 (13.3) 2 (14.3)